Paul Michael Johnson, MSHS, MBA

#ASCO24: GenFleet highlights Phase 2 data on KRAS/EGFR combo in lung cancer https://lnkd.in/gCx3byzU As companies increasingly look to combinations to boost the efficacy of KRAS therapies, a Phase 2 study is offering some of the first clinical evidence for combining KRAS and EGFR in frontline lung cancer. On [...]

Ambry Genetics Data Supports Functional Study of BRCA2, Helping Improve Variant Classification for Hereditary BRCA2-Linked Cancers https://lnkd.in/gBBxP8FM ALISO VIEJO, Calif.–(BUSINESS WIRE)–Ambry Genetics, a leader in clinical genomic testing, today announced its contribution to a study published in Nature that significantly advances our understanding of BRCA2 gene variants. As the uptake of genetic [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

EQBMED launches trial sites tool to assess performance and boost diversity https://lnkd.in/g5vKvi3a The academic-led, industry-partnered collaboration Equitable Breakthroughs in Medicine Development (EQBMED) has released an assessment tool for clinical trial sites to evaluate their ability to perform diverse trials and chart out a path toward improvement in [...]

Aadi pulls commercial-to-preclinical pivot, buying ADCs and selling approved drug to reboot business https://lnkd.in/gEVjG72k Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and licensing antibody-drug conjugates (ADCs) for $44 million upfront. The Los Angeles-based company began looking for [...]

Top stories from cell/gene therapy confab; 2032 deadline to decouple; Patient death in Pfizer trial; and more https://lnkd.in/gpNR9afR Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

SFBN Feed: UCSF Researchers Uncover New Pathway for Molecular Cancer Drug Therapies https://lnkd.in/gR_VHRwu Researchers have discovered a cellular uptake pathway for larger molecules that delivers cell-permeable drugs efficiently. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

CytomX lays off 40% of staff, questions future of Amgen-partnered T-cell engager https://lnkd.in/gMW56vQD CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash. In order to focus its resources on its lead antibody-drug conjugate (ADC) and an array [...]

Nuclein’s DASH® SARS-CoV-2 & Flu A/B Test for Use on the DASH® Rapid PCR System Receives FDA 510(k) Clearance and CLIA Waiver with Key Support from CovarsaDx® Research Team https://lnkd.in/ghCpGpNv LOS ANGELES, Jan. 7, 2025 /PRNewswire/ — CovarsaDx®, a prominent Clinical Research Organization (CRO) renowned for its in vitro diagnostics (IVDs) and medical device expertise, announced today that one of its clinical research study clients, [...]

SFBN Feed: Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism https://lnkd.in/gNsKHA4C REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

Ikena, after tough year of layoffs, merges with Inmagene to focus on phase 2 dermatitis prospect https://lnkd.in/gGcwnnzi After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a sustainable path forward via a merger into privately owned immunology company Inmagene Biopharmaceuticals. The [...]

SFBN Feed: Candid Therapeutics unwraps three new collaborations to discover and develop T-cell engager antibodies https://lnkd.in/gdU48hhM Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped three new research collaborations focusing on autoimmune diseases. Candid will partner with EpimAb Biotherapeutics, Nona [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration https://lnkd.in/gKNBbHPr Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties THOUSAND OAKS, Calif., Jan. 7, 2025 /PRNewswire/ — Capsida Biotherapeutics (“Capsida”) today announced that AbbVie has exercised an option [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

Nuclein’s DASH® SARS-CoV-2 & Flu A/B Test for Use on the DASH® Rapid PCR System Receives FDA 510(k) Clearance and CLIA Waiver with Key Support from CovarsaDx® Research Team https://lnkd.in/ghCpGpNv LOS ANGELES, Jan. 7, 2025 /PRNewswire/ — CovarsaDx®, a prominent Clinical Research Organization (CRO) renowned for its in vitro diagnostics (IVDs) and medical device expertise, announced today that one of its clinical research study clients, [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News